According to a new report published in the Lancet, taking a low dose of GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone) combined with metformin was highly effective in prevention of type 2 diabetes in patients with impaired glucose tolerance, with little effect on the clinically relevant adverse events of these two drugs.
The study included 207 patients with impaired glucose tolerance who were randomly assigned to receive combination rosiglitazone (2 mg) and metformin (500 mg) twice daily or matching placebo for a median of 3·9 years. The researchers found significantly fewer individuals in the active treatment group (14%) developed type 2 diabetes compared with the placebo group (39%).
The research was funded by GlaxoSmithKline.
